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UterusPericonceptional supplementation of folic acid to the diet of women is considered a great success for a public
health intervention. Higher folate status, either by supplementation, or via the mandatory fortiﬁcation of
grain products in the United States, has led to signiﬁcant reduction in the incidence of neural tube defects.
Besides birth defects, folate deﬁciency has been linked to a variety of morbidities, most notably to increased
risk for cancer. However, recent evidence suggests that excess folate may be detrimental — for birth defect
incidence or in the progression of cancer. How folate mediates beneﬁcial or detrimental effects is not well un-
derstood. It is also unknown what molecular responses are elicited in women taking folate supplements, and
thus experience a bolus of folate on top of the status achieved by fortiﬁcation. To characterize the response to
a periconceptional regimen of supplementation with folinic acid, we performed gene expression proﬁling ex-
periments on uterus tissue of pregnant mice with either wildtype alleles or targeted disruption at the folate
receptor 4 locus. We observed that, depending on the genetic background, folinic acid supplementation af-
fects expression of genes that contribute to lipid metabolism, protein synthesis, mitochondrial function,
cell cycle, and cell activation. The extent of the response is strongly modulated by the genetic background.
Finally, we provide evidence that folinic acid supplementation in the mutant paradigm affects histone meth-
ylation status, a potential mechanism of gene regulation in this model.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. Background
Periconceptional folate supplementation has been a public health
success story for the prevention of neural tube defects [1]. The semi-
nal discovery by Smithells [2] was that the incidence of birth defects
such as spina biﬁda was associated with low folate status. Subse-
quently, it was demonstrated that providing women who wish to be-
come pregnant with folate supplements was correlated with a
signiﬁcantly lower incidence of neural tube defects [3], without any
obvious detrimental effects [4]. In the last 15 years, many countries
adopted the recommendation to encourage folate uptake in the
periconceptional period as means of birth defect prevention. The
use of folate supplements, and the introduction of mandatory16 to JMS. Support by COBRE
the PBRC Cell Biology and
ully acknowledged.
earch Center, USA. Tel.: +1 225
baum).
rights reserved.fortiﬁcation of grain products with folic acid in the United States in
1998, have resulted in signiﬁcantly higher folate levels in serum and
red blood cells [1]; these higher folate levels are credited with the
concomitant reduction of birth defect incidence [5] in the last decade.
The mechanism by which folate prevents neural tube defects is
still a mystery. Folate is a carrier for single-carbon moieties, with cru-
cial roles for nucleotide synthesis, amino acid synthesis, as well as
methylation reactions in the cell. Consequences of folate deﬁciency
are best characterized in cancer research, where it is thought that
low folate levels lead to insufﬁcient nucleotide supply, increased in-
corporation of uracil into DNA, increased strand breaks, impaired
DNA repair mechanisms, accumulation of mutations, and overall ge-
nome instability, a hallmark of neoplastic transformation [6,7]. Fur-
thermore, imbalances in DNA methylation were observed, which are
also thought to contribute to genome instability. Therefore, low folate
status is considered to be a risk for the development of neoplasms,
implying that folate fortiﬁcation may alleviate that risk and lead to
beneﬁcial effects for public health beyond prevention of birth defects.
Recently, concerns have arisen that high folate status may be asso-
ciated with consequences that are not unequivocally advantageous
[8]. Folate can act as a mitogen for cancer cells [9], and thereby stim-
ulate the growth of pre-existing neoplasms. In patients with a history
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multiple adenomas and non-colorectal cancer [10]. Tumors originat-
ing from ovarian and prostate cancer express high levels of folate
receptors, indicating that those cells are exceptionally adept at scav-
enging folate to promote their proliferation. In fact, this feature has
been exploited in the design of targeted chemotherapeutic agents
[11], as well as in the invention of molecular tools to visualize folate
receptor-expressing tumors during surgery [12]. High folate status
clearly constitutes a concern with respect to the progression of such
tumors. In the developing rodent embryo, evidence has recently
been presented that very high folate levels in the dam can lead to
an increase in birth defect frequency [13]. Furthermore, in some par-
adigms of genetic neural tube defect susceptibility, higher folate
appeared to be detrimental and lead to higher neural tube defect in-
cidence compared to lower folate status [14]. Together, these data
suggest that high folate consumption may not be entirely beneﬁcial.
On the molecular level, folate status has been associated with gene
expression [15]. Initially, folate-dependent differences in gene expres-
sion levels were attributed to epigenetic events due to the presumed ef-
fects of folate on DNA methylation [16,17]. Yet, methylation reactions
shape other domains of the epigenome besides DNA methylation, and
evidence has arisen that changes in gene expression occur in response
to folate deﬁciency or supplementation without affecting DNA methyl-
ation [18,19]. Many of these studies focused on cancer. However, it is
reasonable to assume that the highest folate levels would be found in
women who, because they want to become pregnant and prevent po-
tential birth defects, take preconceptional folate supplements in addi-
tion to folate intake from fortiﬁed foods. The molecular consequences
of such a bolus of folate, for instance on the female reproductive tract,
are notwell understood. The primary interface betweenmother and de-
veloping embryo is the endometrium of the uterus, where the nutri-
tional interaction is established during the process of implantation, a
crucial step for reproductive success. Whether folate modulates this in-
teraction is currently unclear. Therefore, we decided to investigate the
effects of preconceptional folate supplementation on the female repro-
ductive tract, focusing on the uterus at the time of implantation. Using a
mouse model system, we demonstrate a folate effect on gene expres-
sion in the uterus, and a broader response in mice lacking folate recep-
tor 4, and suggest an effect on histone methylation.
2. Materials and methods
2.1. Folate supplementation and tissue preparation
Purina 5001 (LabDiet, Inc.) was used as diet for all mice. Female
mice of the C57BL/6 strain (or from a strain carrying the Folr4 muta-
tion on the C57BL/6 genetic background) were injected intraperitone-
ally with folinic acid at a dose of 12.5 mg/kg body weight, or with
saline as control. Dams received two injections, at 10 and 3 days be-
fore mating, respectively. Dams were mated to C57BL/6 males; noon
of the day when presence of a vaginal plug could be detected was des-
ignated day 0.5 of gestation. At 3.5 days of gestation, mice were eu-
thanized, uterus tissue was dissected, and either used to extract
RNA, or processed for histology. RNA was extracted using TRIzol
(Invitrogen Life Technologies), quantiﬁed on a NanoDrop ND-1000
spectrophotometer, and stored at −80 °C for further analysis.
2.2. Mice lacking Folr4
Mice with a mutation in the Folr4 gene were generated via homol-
ogous recombination in mouse embryonic stem cells. For this pur-
pose, a construct was made where the ﬁrst two coding exons of the
gene were ﬂanked by loxP recombination sites, followed by the
gene for neomycin resistance and third loxP site. Electroporation of
the construct, selection of ES cell clones with the correct constellation
at the Folr4 gene, and generation of chimeric mice were done asdescribed [20]. Homozygous mice carrying the ﬂoxed locus were via-
ble. To generate a null mutation, homozygous Folr4FL mice were
crossed to mice expressing Cre recombinase in the oocyte [21],
resulting in heterozygous offspring with one allele of the Folr4 gene
exhibiting a deletion of the ﬁrst two coding exons. PCR analysis of
the locus produced an amplicon of 413 bp indicative of the deletion,
compared to an amplicon of 1365 bp from the wildtype allele. Mice
with this Folr4 null allele were backcrossed to the C57BL/6 genetic
background for more than 10 generations. Heterozygous mice were
used to generate the homozygous Folr4 mutant female mice used in
this study. All procedures involving animals were approved by the In-
stitutional Animal Care and Use Committee.
2.3. Gene expression proﬁling
Affymetrix Mouse 430 2.0 microarrays were used to perform gene
expression proﬁling experiments as described previously [22]. We
processed three RNA samples from wildtype C57BL/6 dams, four from
wildtype C57BL/6 dams treated with folinic acid, three from Folr4 mu-
tant dams, as well as four from Folr4 mutant dams supplemented with
folinic acid for array hybridization. All sampleswere obtained from indi-
vidual animals. Tissue dissection and RNA extractionwere performed on
the same day, and all further processing, including array hybridizations,
was done in parallel to ensure technical consistency between samples.
Arrays were normalized as described [22], and array data were
processed to identify differential gene expression using CyberT software
[23]. We used the implementation of the software available at http://
cybert.ics.uci.edu/, employing a Bayes-regularized t-test after applying
variance stabilized normalization [24]. Annotation for molecular func-
tion was performed using GO terms, with manual curation based on
MGI (http://www.informatics.jax.org/) and GeneCards (http://www.
genecards.org/). Results from probes for non-coding RNAs, or probes
where gene identity was missing, were omitted. Data for one probe
per gene were retained for the ﬁnal list. When a gene was represented
by more than one probe, duplicates were eliminated based on criteria
of high p-value, low expression and low fold-change. In the very few
cases where duplicates displayed opposite directions of change for the
same gene, the genewas removed from consideration. Pathway analysis
was performed using the DAVID (http://david.abcc.ncifcrf.gov/) [25]
suite of tools; adjusted p-values given in the Results section (padj)
refer to p-values obtained after Benjamini–Hochberg correction. Visual-
ization of expression differences was done in Microsoft Excel. Lists of
folate- and genotype-responsive probes are presented in Supplementa-
ry Table 1. All microarray analyses reported here have been deposited to
GEO (http://www.ncbi.nlm.nih.gov/geo/; accession numberGSE36974).
2.4. Expression measurements
Validation of expression measurements for selected genes was
performed by real-time quantitative PCR on an Applied Biosystems
7900 system as described previously [26]. Expression measurements
were generated using the gene for DNA polymerase subunit epsilon 4
as the reference gene for normalization [26]. Primer sequences are
listed in Supplemental Table 2. Three replicate assays per sample were
performed, and statistical evaluation of PCR data was done via two-
tailed t-test based on at least n = 4 samples; samples included those
used for microarray as well as independently generated samples.
2.5. Histology
Parafﬁn-embedded tissue sections [27] or cryosections [28] were
processed for in situ hybridization with digoxigenin-labeled antisense
riboprobes as described previously. For immunohistochemistry with
antibodies against histone H3 lysine K4 trimethylation (Millipore,
Billerica, MA), frozen uterus tissue was sectioned at 16 μm, ﬁxed in 1%
formaldehyde in PBS, washed, blocked in PBS containing 2% goat
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4 °C, washed in PBS, and developed with goat-anti rabbit-Alexa 594
secondary antibody (Invitrogen, Carlsbad, CA). Brightﬁeld images
were recorded on a Leica Z16 macroscope, whereas ﬂuorescent images
were captured on a Leica TCS SP5 confocal microscope, using the same
instrument settings for all specimens, respectively.
3. Results
The focus of folate supplementation before and at onset of pregnancy
has always been on pregnancy outcome and prevention of birth defects.
Very little attention, however, has been paid to molecular responses to
folate in the expectingmother, where the consequences of a boost in fo-
late levels are not well understood. To gain insights into the molecular
consequences of preconceptional folate supplementation on female re-
productive tissues, we conducted an experiment where mice received
two injections of folinic acid (a stable folate derivative) at 10 and
3 days before mating, respectively. Considering that implantation is a
crucial step in reproductive success, we focused on uterus tissue at
3.5 days after mating, the time when the blastocyst reaches the uterus.
With the main emphasis on the response to folinic acid, we processed
uterus tissue for transcription proﬁling via microarrays, and analyzed
(i) gene expression in the uterus of wildtype mice in response to folinic
acid supplementation, (ii) gene expression in the uterus in response toFig. 1. Transcriptional responses to folate supplementation in the uterus. A. Comparison of
(FA_WT) mice revealed a moderate response consisting of predominantly small changes:
830 probes were altered (406 with increased expression level, 424 with decreased express
(188 increased, 246 decreased), whereas at 2-fold or greater change, only 89 gene prob
Benjamini–Hochberg correction (padj b 0.1). All probes with a p-value below 0.05 in a Bayes-
against the observed fold change. Marked gene probes correspond to those genes valida
Folr4-mutant (KO) and folinic acid (FA) supplemented mutant (FA_KO) mice demonstrate
average expression levels, 2642 probes were altered (1177 expression levels increased, 146
duced to 1786 probes (885 increased, 901 decreased), whereas at 2-fold or greater change,
probes, 448 passed a Benjamini–Hochberg correction (padj b 0.1). All probes with a p-valu
correspond to those genes validated by quantitative PCR (see Tables 1 and 3). C. Compariso
tissue. Only 208 gene probes are common between the two responses; out of those, 144 cha
altered expression in a discordant manner. D. Annotation of differentially expressed genes by
tation in either wildtype (FA_WT vs. WT) or Folr4 mutant (FA_KO vs. KO) tissue. Note the la
function), protein processing (including localization), and RNA binding (including ribonuclfolinic acid in the presence of a genetic liability in form of a mutation
at the gene for folate receptor 4, and (iii) explored to what extent sup-
plementation with folinic acid may be able to reverse expression
changes brought about by the Folr4 deﬁciency.
3.1. Identiﬁcation of folate-responsive genes in peri-implantation mouse
uterus
The response of mouse uterus tissue to folinic acid supplementa-
tion is shown in Fig. 1A, based on statistical signiﬁcance in a
Bayes-regularized t-test (p b 0.05). We found a moderate magnitude
of the transcriptional response to folate supplementation before preg-
nancy, with 188 gene probes showing a folate-dependent 1.5-fold or
higher increase in expression level, and 246 gene probes exhibiting a
decrease of expression. Lowering the fold-change cutoff to 1.2-fold in
either direction (using the same statistical test), we detected a total of
830 gene probes that change expression in response to folate, with
406 probes showing increase, and 424 probes showing a decrease in
expression levels. This suggested that the response to folate in this
paradigm is comprised by relatively small changes of expression
levels for a moderately large number of genes. Genes of the folate
cycle were unaffected, as were genes encoding methyltransferases.
We chose ﬁve genes (2 up- and 3 down-regulated) that represented
different levels of expression for validation of the array-basedgene expression proﬁles in normal (WT) and folinic acid (FA) supplemented normal
at a 1.2-fold or greater difference between average expression levels in each group,
ion level); at a 1.5-fold or greater difference, this number was reduced to 434 probes
es were detected (47 increased, 42 decreased). Of the 830 gene probes, 4 passed a
regularized t-test are shown, with their respective expression level on the array plotted
ted by quantitative PCR (see Table 1). B. Comparison of gene expression proﬁles in
d a more vigorous transcriptome response: at a 1.2-fold or greater difference between
5 expression levels decreased); at a 1.5-fold or greater difference, this number was re-
only 451 gene probes were detected (299 increased, 152 decreased). Of the 2642 gene
e below 0.05 in a Bayes-regularized t-test are shown in the plot. Marked gene probes
n of the response to folinic acid supplementation between wildtype and Folr4 mutant
nge expression in a fashion concordant between the two genotypes, whereas 64 show
molecular function comprising the transcriptional response to folinic acid supplemen-
rge segments for metabolism (including oxidative phosphorylation and mitochondrial
eoprotein complexes).
Table 2
Summary of top-scoring categories in DAVID pathway analysis.
Pathway analysis was performed using the DAVID (http://david.abcc.ncifcrf.gov/) [25]
suite of tools; adjusted p-values (padj) refer to p-values obtained after Benjamini–
Hochberg correction. All analyses were performed with the default settings and classi-
ﬁcation stringency at “medium”.
Increase Decrease
Go term padj Genes Go term padj Genes
A: Folinic acid-supplemented wildtype vs. wildtype
Lipid
metabolic
process
0.011 29 Ribonucleoprotein
complex
4.3 × 10−06 30
Structural
constituent
of ribosome
2.5 × 10−05 11
mRNA
metabolic
process
6.4 × 10−04 20
Vasculature
development
0.016 15
B: Folinic acid-supplemented Folr4 mutant vs. Folr4 mutant
Immune
system
process
1.9 × 10−26 115 Structural
constituent
of ribosome
2.5 × 10−59 83
Leukocyte
activation
1.5 × 10−09 38 Cell cycle 1.5 × 10−10 83
T cell
activation
1.3 × 10−06 23 m-phase 2.3 × 10−10 51
Regulation of
immune
response
2.2 × 10−09 35 Mitochondrion 2.6 × 10−10 141
Cytokine
binding
4.8 × 10−06 20 Oxidative
phosphorylation
0.064;
5.8 × 10−14
20
Mitochondrial
lumen
3.5 × 10−03 22
C: Folr4 mutant vs. wildtype
Structural
constituent
1.7 × 10−21 36 Defense
response
8.7 × 10−05 25
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direction of the expression change with statistical signiﬁcance as de-
termined by a t-test (Table 1); the assay for Zfand3 did not reach sta-
tistical signiﬁcance.
In order to determine which biological pathways may be affected
by folate supplementation, we used the genes derived with greater
than 1.2-fold change as well as statistical signiﬁcance. Annotation
for molecular function of the products encoded by differentially
expressed genes revealed (Fig. 1D) that molecules involved in metab-
olism (11.4%), signal transduction (10.7%), RNA binding (8.5%), tran-
scriptional regulation (8.3%), as well as receptors and growth factors
(8.1%) comprised the largest groups. Using the DAVID suite of tools
(http://david.abcc.ncifcrf.gov/) [25] for further functional annotation,
we analyzed gene groups with increased or decreased expression
separately; the results are summarized in Table 2, section A. Among
the genes with increased expression, we found enrichment for the
gene ontology term ‘lipid metabolic process’. In the group of genes
with decreased expression, the gene ontology terms ‘ribonucleopro-
tein complex’, ‘mRNA metabolic process’ and ‘structural constituent
of ribosome’ were detected. Together, these results suggest that
folinic acid supplementation decreases the expression of components
of the protein synthesis mechanism in cells of the uterus, and may in-
crease lipid metabolism.
3.2. Identiﬁcation of folate-responsive genes in Folate receptor 4-deﬁcient
mice
Interestingly, we observed a much broader transcriptional re-
sponse to folinic acid supplementation in uteri derived from mice
with a deletion of the Folr4 gene (Fig. 1B). Applying the same criteria
as before for wildtype dams (more than 1.2-fold change in either di-
rection, p b 0.05), we detected 2642 gene probes in Folr4 mutants
that responded to folate, with 1177 probes increasing, and 1465
probes decreasing in their expression levels. 451 probes showed
more than 2-fold change; 299 of those showed increased expression
in response to folate supplementation, whereas 152 responded with
a decrease. The qPCR validation of the expression changes of nineTable 1
Gene expression analyses by RT-PCR.
Representative genes at different expression levels were chosen to validate the micro-
array results. For the comparison of wildtype vs. folinic acid-supplemented wildtype, 5
genes are shown. We observed concordant expression changes in the array and the
qPCR, although not all PCR assays reach statistical signiﬁcance in a t-test. For the com-
parison of mutant vs. folinic acid-supplemented mutant, 6 genes are shown that repre-
sent differentially regulated genes at various expression levels according to the array
data. Furthermore, three genes of the folate pathway were among the genes of the
folinic acid response: Dhfr, Mtr, and Tyms all show decreased expression in response
to folinic acid in the mutant.
Gene symbol Microarray qRT-PCR
Fold change p-value Fold change p-value
FA_WT vs. WT
Csf3 2.07 0.001 2.15 0.029
Marcks −2.11 0.000 −1.34 0.027
Scl2a3 1.95 0.002 2.02 0.032
Xlr3a −2.42 0.000 −2.49 0.020
Zfand3 −3.29 0.000 −1.17 0.051
FA_KO vs. KO
Bcl11b 2.80 0.002 5.00 0.009
Calb1 −3.41 0.000 −5.05 0.024
Lrp2 −4.13 0.000 −5.95 0.044
Oxtr 2.41 0.000 2.64 0.053
Slc6a14 −3.85 0.000 −7.97 0.023
Ttr −4.49 0.000 −8.37 0.001
Dhfr −1.48 0.029 −1.53 0.049
Mtr −1.83 0.012 −1.91 0.030
Tyms −2.12 0.000 −2.49 0.005
of ribosome
Mitochondrion 0.1 33 Immune
response
1.8 × 10−07 31
D: Folinic acid-supplemented Folr4 mutant vs. Folr4 mutant compared to Folr4
mutant vs. wildtype
Immune
system
process
6.6 × 10−06 24 Structural
constituent
of ribosome
2.4 × 10−29 36
Mitochondrion 0.036 33
Glutathione
transferase
activity
0.0054 6genes representing different levels of expression on the array is
shown in Table 1.
Among genes of the folate cycle, we ﬁnd Dhfr, Mthfd1, Mthfd1l,
Mthfd2, Mthfr, Mtr, Shmt1, Slc46a1, and Tyms mildly deregulated;
only Tyms and Mthfd2 showed more than a 2-fold expression change.
qPCR analysis of Dhfr, Mtr and Tyms conﬁrmed direction and magni-
tude of the expression change initially observed in the microassay
experiment. Notably, we also detected downregulation of Lrp2
(Megalin), which can bind soluble folate receptors; this change in ex-
pression was apparent on the array as well as in qPCR assays. We ob-
served moderate deregulation of genes encoding methyltransferases,
but no coordinate change in one direction: Ezh1, Mettl7a1, Mll5,
Pcmtd1, Pcmtd2, Setd3, Suv420h1, Suv420h2, and Tgs1 exhibited an av-
erage fold change of 1.51; and Alkbh8, Dnmt1, Lcmt1, Mtr, N6amt2,
Nsd1, Prmt1, Setdb1, and Trmt112 an average fold change of−1.51.
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sponse in Folr4 mutant uterus was primarily composed of moderate
magnitude changes for a large group of genes. Fig. 1D shows that the
distribution of encoded products follows a similar pattern as in the
comparison of supplemented to unsupplemented wildtype females,
although genes encoding ‘signal transduction’ molecules (15.2%) were
enriched compared to wildtype. Groups comprising ‘metabolism’
(11.7%), ‘receptors and growth factors’ (9.8%) and ‘RNA binding’
(8.7%) were similarly represented, but in absolute number, there were
3–4 fold more genes responding to folinic acid in the Folr4 mutants.
We obtained further annotation information using DAVID tools, an-
alyzing the groups of up- and down-regulated genes separately
(Table 2, section B). Among genes with increased expression in re-
sponse to folinic acid, gene ontology terms related to immune response
were highly enriched. In the group of genes that exhibit a decrease in
expression as response to folinic acid supplementation in the mutant,
the term ‘structural constituent of ribosome’was strongly represented,
paralleling the supplementation response in wildtype mice. However,
considering individual gene identities, we noted relatively little concor-
dance in the response to folinic acid between wildtype and Folr4 mu-
tants (Fig. 1C): only 208 gene probes were found to overlap between
the two supplementation paradigms, and of these, only 144 showed a
concordant direction of change.
Interestingly, strong associations to the GO terms ‘cell cycle’,
‘M-phase’, ‘mitochondrion’, ‘oxidative phosphorylation’ and ‘mitochon-
drial lumen’ were found among the genes with decreased expression.
Together, this suggested that folinic acid supplementation in Folr4 mu-
tant mice, in addition to eliciting a much broader transcriptomic re-
sponse, may also lead to a dampening of cellular processes such as
mitosis, possibly through decreased functionality of ribosomes which
would affect protein synthesis, and to a reduction in mitochondrial
functionality which could affect energy homeostasis of cells. The in-
triguing ﬁnding of extensive differences in the folinic acid response
prompted us to investigate in more detail the differences between tis-
sues from unsupplemented wildtype and mutant females.
3.3. Uterus gene expression modulated by a mutation in the gene for
folate receptor 4
Folr4 is expressed in a restricted pattern in cells of the endometri-
um in uterus tissue obtained from a wildtype mouse (Fig. 2A and B).
The Folr4 mutation deletes the ﬁrst two coding exons of the Folr4
gene. Homozygous Folr4 mutant mice can be recovered frommatings
of heterozygote mice at Mendelian ratio. There was no evidence ofFig. 2. Expression of Folr4 in the uterus and altered gene expression in Folr4 mutant uterus. A
hybridization. Folr4 mRNA was detected in cells of the endometrium. B. Expression of Folr4
protein expression (green) is limited to the endometrium. In addition a few solitary cells in
than the DIG-labeled riboprobe under these conditions; e, endometrium; l, lumen of the ut
mutant mice (KO) to uterus tissue of wildtype mice (WT). At a 1.2-fold or greater differenc
increased expression level in the mutant, 386 with decreased expression level); at a 1.5-fold
creased), whereas at 2-fold or greater change, only 87 gene probes were detected (40 increa
(padj b 0.1). All probes with a p-value below 0.05 in a Bayes-regularized t-test are shown,
change. Marked gene probes correspond to those genes examined by quantitative PCR.birth defects, nor of overt morphological differences in the uterus at
the time of isolation. Allowing a minimum fold-change of 1.2-fold in
either direction at p b 0.05 in a Bayes-regularized t-test, we detected
992 gene probes with altered expression when comparing Folr4 mu-
tant to wildtype: 606 with increase, and 386 with decrease of expres-
sion (Fig. 2C). At 2-fold change, 87 probes were detected, 40 with
increase and 47 with decrease of expression. Such a moderate re-
sponse is consistent with the fact that Folr4 is not expressed through-
out the uterus, but limited to the endometrium and solitary cells in
the uterine parenchyma. Other folate receptors and folate pathway
genes were not changed in their expression. Using DAVID, we ﬁnd
that the gene ontology term ‘structural constituent of ribosome’ is
signiﬁcantly enriched in the group of genes with increased expres-
sion, whereas the terms ‘defense response’ and ‘immune response’
were found to be enriched in the group of genes with decreased ex-
pression in the Folr4 mutant. Results from the pathway analyses are
summarized in Table 2 section C.
This suggested that the lack of Folr4 may have a rather moderate
effect on the development of uterus tissue, consistent with the ab-
sence of overt morphological differences in uterus tissue of mutant
dams compared to wildtype. Furthermore, the decreased expression
of genes associated with the term ‘immune response’ and ‘defense re-
sponse’ in the mutant may be related to the expression of Folr4 on
regulatory T-cells [29].
3.4. Reversal of genotype-dependent changes by folate supplementation
When analyzing genotype-mediated differential gene expression
in Folr4 mutant dams, we noted that 562 gene probes (representing
451 genes) were also responsive to folinic acid supplementation
(Fig. 3A), changing their expression levels between normal mutant
and supplemented mutant. Intriguingly, except for 2 genes, all those
gene probes show a statistically signiﬁcant discordant response in
the two comparisons: 359 of 360 probes (representing 279 genes)
with increased expression in the unsupplemented mutant compared
to wildtype displayed a decrease of expression in the folinic acid-
supplemented mutant compared to the unsupplemented mutant
(Fig. 3B). Likewise, 201 of 202 probes (representing 172 genes)
with decreased expression in the mutant when compared to wildtype
exhibited an increase of expression in the folinic acid supplemented
mutant uterus. The two genes that do not conform are Cxcl17 and
Pdgfd. In total, approximately 57% of the gene probes showing
changes in expression attributable to genotype also respond to folinic
acid supplementation in the mutant; notably, the magnitude of. Expression of Folr4 mRNA in the uterus at 3.5 days of gestation as visualized by in situ
protein visualized by immunohistochemistry. Similar to the in situ hybridization, Folr4
the uterine parenchyma were detected, suggesting that the antibody is more sensitive
erus. C. Transcriptome analysis comparing gene expression in uterus tissue from Folr4
e between average expression levels in each group, 992 probes were altered (606 with
or greater difference, this number was reduced to 567 probes (305 increased, 262 de-
sed, 47 decreased). Of the 992 gene probes, 20 passed a Benjamini–Hochberg correction
with their respective expression level on the array plotted against the observed fold
Fig. 3. Folinic acid can correct changes in expression caused by the Folr4 mutation. A. Comparison of statistically signiﬁcant responses (p b 0.05 in a Bayes-regularized t-test) in
Folr4−/− and normal dams (KO vs. WT, 992 probes), and in FA-supplemented Folr4−/− and non-supplemented Folr4−/− dams (FA_KO vs. KO, 2642 probes), respectively, revealed
562 probes that responded under both conditions. B. These 562 probes showed discordant directions for the changes in expression levels when compared between the two con-
ditions: 360 probes show increased expression in the mutant vs. the wildtype, whereas 202 show decreased expression. These probes exhibit the opposite expression change
when comparing the supplemented mutant to the mutant (except for 2 probes), indicating that FA can, in part, rectify the effect of the Folr4 mutation. Y-axis: fold-change between
average expression levels for any given gene in each comparison.
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changes induced by folinic acid in the mutant: absolute fold-changes
for each gene are highly similar, yet, the direction of change is back
towards levels comparable to unsupplemented wildtype.
Interestingly, gene ontology terms ‘structural constituent of ribo-
some’ and ‘mitochondrion’, which were associated with increased
gene expression levels due to mutant genotype, are now found in
the group of genes with decreased expression in response to folinic
acid. Conversely, the term ‘immune system process’ attached to
genes with decreased expression level due to mutant genotype, but
these are now found reversed to normal by folinic acid supplementa-
tion (Table 2, section D).
We sought to conﬁrm this ﬁnding of inverse direction of change for
selected genes by measuring expression levels by quantitative real-
time PCR. Eight genes were chosen for this analysis: Fst, Pcx, Tpd52l1,
and Vit are four genes that were up-regulated in the mutant compared
to wildtype, whereas Ccr2, Fnip1, Slfn5, and Tmem173 represent four
genes with decreased expression in the mutant (Fig. 2C). In themicroar-
ray experiment, all eight genes showed a reversal of the initial expression
levels in the mutant by folinic acid supplementation. In the validation
study (Table 3), we were able to conﬁrm the initial observations: Fst,
Pcx, Tpd52l1, and Vit expression levels were increased in the mutant
compared to the wildtype, and Ccr2, Slfn5, Fnip1, and Tmem173 levels
were decreased, although the comparison between groups did notTable 3
Folinic acid-mediated reversal of gene expression changes in Folr4 mutant mice.
We observed 562 gene probes that appear to reverse the expression change elicited by the
idation by qPCR: four genes that were initially up-regulated in the mutant vs. the wildtype
genes with the opposite pattern of gene expression changes: reduced expression in mutant
compared to unsupplemented mutant. In all cases, the direction of the expression change co
in a t-test.
Gene symbol Microarray
KO vs. WT FA_KO vs. KO
Fold change p-value Fold change p-v
Fst 2.92 0.042 −2.98 0.04
Pcx 1.85 0.009 −2.56 0.03
Tpd52l1 1.67 0.008 −2.07 0.00
Vit 1.82 0.041 −1.96 0.03
Ccr2 −2.19 0.017 2.55 0.01
Fnip1 −1.47 0.046 1.91 0.02
Slfn5 −1.84 0.042 1.81 0.04
Tmem173 −1.65 0.009 2.49 0.02reach statistical signiﬁcance for the latter two genes. As in the micro-
arrays, opposing direction of changes in expression of these genes were
found when comparing folinic acid-supplemented mutant samples to
non-supplemented mutant samples: supplementation decreased Fst,
Pcx, Tpd52l1, and Vit, and increased Ccr2, Fnip1, Slfn5, and Tmem173.
Together, the results demonstrate the reversal of mutation-dependent
molecular alterations by folinic acid supplementation.
3.5. Histone methylation patterns in Folr4 mutant uterus
Finally, to explore potential mechanisms for folate-dependent gene
regulation, we investigated whether the status of histone H3 lysine K4
trimethylation (H3K4me3), a histone modiﬁcation typically associated
with promoters of actively transcribed genes, would be responsive to
folinic acid supplementation. To this end, we stained cryosections of
uterus tissue with an antibody speciﬁc for trimethylation at lysine 4 of
histone 3 (H3K4me3); due to the stronger transcriptomic response to
supplementation, we chose uterus tissue from mutant dams in this
study and compared supplemented mutant to non-supplemented mu-
tant. We observed a signal for H3K4me3 in uterus tissue from a non-
supplemented Folr4 mutant mouse (Fig. 4A) in many, but not all, cell
nuclei on a representative section of uterus tissue. In parallel, staining
for H3K4me3 in uterus tissue from a folinic acid-supplemented mutant
revealed a brighter signal in nearly all cell nuclei of a section (Fig. 4B).Folr4 mutation when supplemented with folinic acid. Eight genes were chosen for val-
, yet showed a decrease in expression in folinic acid-supplemented mutants, and four
compared to wildtype, and increased expression in folinic acid supplemented mutant
uld be conﬁrmed by qPCR, although not all qPCR assays reached statistical signiﬁcance
qRT_PCR
KO vs. WT FA_KO vs. KO
alue Fold change p-value Fold change p-value
8 3.31 0.018 −3.28 0.130
5 2.13 0.042 −5.03 0.026
3 1.62 0.023 −1.49 0.296
7 1.68 0.032 −2.04 0.003
2 −1.98 0.002 2.27 0.028
4 −1.40 0.118 1.34 0.036
7 −1.53 0.021 1.24 0.361
5 −1.30 0.156 1.87 0.042
Fig. 4. Histone methylation responses to folinic acid supplementation. A. Cryosection of a Folr4−/− uterus stained with an antibody against trimethylated histone H3 lysine 4
(H3K4me3, red). B. Folr4−/− uterus after supplementation with folinic acid (FA), stained, processed and imaged in parallel under identical conditions as in A. Stronger and
more widely distributed staining indicates that folinic acid stimulates histone methylation in the uterus, in a pattern that appears broader than the expression pattern of Folr4. Sec-
tions in A, and B were counterstained with Dapi to reveal nuclei. C. Expression pattern of Follistatin (Fst) in uterus tissue at 3.5 days of gestation occurs in a pattern different from
the expression of Folr4. Fst was never detected in the endometrium, but appears to be restricted to uterine glands.
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tion of H3K4 trimethylation levels in uterus tissue, with strong repre-
sentation in the endometrium. As the H3K4me3 staining pattern,
which included the domain of Folr4 expression, also contained amajor-
ity of Folr4 non-expressing cells in the uterus, the altered histonemeth-
ylation status may contribute to the altered gene expression levels in
response to folinic acid.
4. Discussion
4.1. Transcriptional effects of folate supplementation in the mouse uterus
In this study, we demonstrate that preconceptional supplementa-
tion with folinic acid alters the transcriptome of uterus tissue in a
mouse model. The overall responses were moderate in magnitude
of expression changes, which may be related to the fact that we mea-
sured transcriptome responses seven days after the last injection of
folinic acid. We ﬁnd that components of RNA processing and protein
synthesis pathways respond with decreased gene expression. Genes
in these categories were also downregulated by folinic acid in mice
carrying the Folr4 mutation, suggesting that under our experimental
conditions, folinic acid may have a dampening effect on fundamental
cellular processes. Such an action would be contrary to what one
might expect in light of the notion that folate can act as a mitogen
in cancer cells [9,30,31]. Our histological observations provided no in-
dication for the notion that folate acts as a mitogen in the uterus: cell
density (as detected by nuclear staining with DAPI) did not differ be-
tween folinic acid-supplemented and unsupplemented specimen
(data not shown). Yet, given that we investigated one time point
only, this aspect warrants further investigation.
4.2. Identiﬁcation of mitochondrial pathways as targets of folate
supplementation
In Folr4 mutants, the uterine response to folinic acid supplemen-
tation involved a much larger number of genes, and this broader re-
sponse contained, in top scoring categories, genes associated with
immune function, cell cycle regulation, and mitochondrial function.
Pathways related to immune function were increased by folinic acid
in the mutant, whereas genes associated with cell cycle and mito-
chondrial function were decreased by supplementation. The link to
mitochondrial function is in line with a recent report on gene expres-
sion proﬁles in response to dietary folate status in mice that were het-
erozygous for a mutation in Lrp6, a gene encoding a Wnt co-receptor
[30]. In that study, genes for oxidative phosphorylation and mito-
chondrial function were found to respond to folate, both in embryon-
ic crania at 9.5 days of gestation, as well as in adult liver. Ourexperiments, in Folr4 mutant mice, now provide further support for
the idea that mitochondrial biology may be affected by folate. Folates
themselves have been considered to be antioxidants [31], and as such
could potentially inﬂuence levels of oxidative stress, a factor that has
been implicated in birth defect etiology. Notable from our results is
that in mutant tissue, folinic acid supplementation downregulated
the expression of genes encoding components of the respiratory
chain, suggesting that high doses of folinic acid may negatively affect
mitochondrial energy metabolism, and possibly mitochondrial func-
tion in general.4.3. Maternal genotype modulates the response to folate
supplementation
Transcriptional responses to external stimuli, such as the presence or
absence of a micronutrient, are highly dependent on the status of the
cell in question: pre-existing conditions, such as transcription factor
repertoire, or epigenetic states, shape the capability of the cell to re-
spond. The experiment conducted with Folr4 mutant mice underscores
this notion. Under identical conditions of folinic acid concentration and
schedule of supplementation, the Folr4-deﬁcient mutants exhibited a
much broader transcriptional response to folate compared to wildtype
mice (see Fig. 1C). Yet, when we compared the group of genes affected
by folinic acid in the wildtype to the genes affected by folinic acid in
the mutant, we found that the overlap between the responses was
small, indicating that the mutant genotype fundamentally alters the
transcriptome response to supplementation. This result in the mutant
paradigm indicates that a signiﬁcant interaction occurred between fo-
late supplementation and genotype in the mutant female tissue. Thus,
our work extends the cases of folate-dependent gene–environment in-
teractions to uterus.
Interestingly, the much broader transcriptional response in Folr4
mutants occurs even though the majority of cells in the wildtype
uterus do not express Folr4 (see Fig. 2), indicating that other trans-
porters are involved. Uterus tissue also expresses folate receptors
Folr1 and Folr2, as well as the folate transporters Slc46a1 (proton-
coupled folate transporter) and Slc19a1 (reduced folate carrier).
Slc19a1, speciﬁcally, is ubiquitously expressed, which should permit
folate entry into nearly every cell, particularly so under folate supple-
mentation conditions. The wide distribution of the H3K4me3 signal in
the supplemented mutant uterus underscores this interpretation, as it
indicated that almost the entire tissue is capable of responding to
folinic acid.
Under the theoretical assumption that the targeted disruption of
the Folr4 gene has cell-autonomous effects, the parsimonious predic-
tion would be that in the mutant, molecular responses to the genetic
manipulation would be restricted to cells in the uterus that normally
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Folr4 respond similarly to folinic acid supplementation, regardless
whether they are in a wildtype or mutant animal; considering that
the majority of cells in uterus are Folr4 negative, one might even ex-
pect the overall tissue responses to be quite similar. However, our re-
sults clearly demonstrate that this is not the case: quantity (number
of genes) and quality (types of genes and associated pathways) of
the response are altered by Folr4 deletion. This prompts our conclu-
sion that the Folr4 mutation has non-cell-autonomous effects on
neighboring cells, and that these effects also alter the response to
folinic acid supplementation. Intriguingly, more than 50% of the
genes affected by Folr4 deﬁciency in the mutant (Fig. 3A) respond
to folinic acid supplementation, providing evidence that the Folr4
mutation and folinic acid supplementation converge on some path-
ways common to both paradigms. The most prominent pathways in
our analysis are related to immune function and mitochondrial biolo-
gy (Table 2 section D).
Additionally, it is conceivable that the Folr4 disruption, through bio-
logical action at earlier stages in development of females, may affect the
uterine tissue cell-non-autonomously. Support for this possibility
comes from genes like Follistatin: Fst responds to genotype and supple-
mentation in opposing fashion, yet it is expressed in cells outside of the
Folr4 expression domain (Fig. 4C), constituting an example for
non-cell-autonomous regulation of expression by genotype. Taken to-
gether, our results strongly suggest that the initial lack of Folr4 predis-
poses cells outside of the Folr4 expression domain to mount a broader
transcriptomic response than in the wildtype. Thus, genotype has a
strong modifying effect on the response to folate supplementation.
While the underlying mechanism for cell-non-autonomous actions of
Folr4 remains to be investigated, we conclude that preexisting condi-
tions, such as e.g. genetic liabilities, or susceptibilities introduced by en-
vironmental exposure, can exert a signiﬁcant inﬂuence on size and
repertoire of the response to folate supplementation. Thus, responses
to folate can bemodulated, andmay depend on pre-existing conditions
such as genetic, nutritional, or metabolic susceptibilities.
Furthermore, the notion that responses to folate are strongly mod-
ulated by genetic factors is underscored by the recent ﬁnding that fo-
late status in mouse mutants of neural tube defect genes is not
unequivocally beneﬁcial: higher folate status relieved the neural
tube defect burden in some of these mutant mouse strains, but aggra-
vated it in others [14], demonstrating that the response to folate was
highly dependent on the genetic background. In contrast to the
mouse strains utilized in that study, homozygous Folr4 mutant em-
bryos of both sexes develop normally and do not display neural
tube defects; thus, they are clearly unsymptomatic with respect to
neural tube defects. Yet, the signiﬁcant modulation of the response
to folinic acid by the Folr4 genotype raises the question how many
other ‘phenotypically unsymptomatic’ genetic variations or muta-
tions could have the potential to modulate the response to folate.
The answer to this question has considerable implications for folate
supplementation and fortiﬁcation in humans. While functional conse-
quences of human DNA variation are often milder than what is ob-
served in inbred mouse models with targeted gene disruptions, it
still stands to reason that folate also interacts with the genetic back-
ground in the human population, and may thus elicit distinct molec-
ular responses in different individuals. If this were the case, health
beneﬁts from folate may vary by individual genetic constitution as
well. Therefore, the concept that folate is unequivocally beneﬁcial
may deserve critical re-evaluation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.028.
Acknowledgements
J. Michael Salbaum and Claudia Kappen designed and supervised
the study, Claudia Kruger contributed to the microarray analyses,J. Michael Salbaum performed the histological experiments; all
three authors participated in analysis and interpretation of the
data, and J. Michael Salbaum composed the ﬁgures and wrote the
manuscript, which Claudia Kappen edited, with J. Michael Salbaum
bearing primary responsibility for ﬁnal content. All authors read
and approved the submitted manuscript. The authors declare that
they have no conﬂicts of interest. This work was supported
by grant NIH-R21-HD48516 to JMS. Support by COBRE NIH-
P20GM103528 and NORC NIH-P30DK072476 to the PBRC Cell Biolo-
gy and Bioimaging Core and the PBRC Genomics Core is gratefully
acknowledged.References
[1] S.G. Obican, R.H. Finnell, J.L. Mills, G.M. Shaw, A.R. Scialli, Folic acid in early
pregnancy: a public health success story, FASEB J. 24 (2010) 4167–4174.
[2] R.W. Smithells, S. Sheppard, C.J. Schorah, Vitamin deﬁciencies and neural tube de-
fects, Arch. Dis. Child. 51 (1976) 944–950.
[3] R.W. Smithells, S. Sheppard, C.J. Schorah, M.J. Seller, N.C. Nevin, R. Harris, A.P.
Read, D.W. Fielding, Apparent prevention of neural tube defects by
periconceptional vitamin supplementation, Arch. Dis. Child. 56 (1981) 911–918.
[4] A. Milunsky, H. Jick, S.S. Jick, C.L. Bruell, D.S. MacLaughlin, K.J. Rothman, W.
Willett, Multivitamin/folic acid supplementation in early pregnancy reduces the
prevalence of neural tube defects, JAMA 262 (1989) 2847–2852.
[5] G.J. Locksmith, P. Duff, Preventing neural tube defects: the importance of
periconceptional folic acid supplements, Obstet. Gynecol. 91 (1998) 1027–1034.
[6] M. Fenech, The role of folic acid and vitamin B12 in genomic stability of human
cells, Mutat. Res. 475 (2001) 57–67.
[7] O. Sieber, K. Heinimann, I. Tomlinson, Genomic stability and tumorigenesis,
Semin. Cancer Biol. 15 (2005) 61–66.
[8] C.M. Ulrich, J.D. Potter, Folate supplementation: too much of a good thing? Cancer
Epidemiol. Biomarkers Prev. 15 (2006) 189–193.
[9] Y.I. Kim, Role of folate in colon cancer development and progression, J. Nutr. 133
(2003) 3731S–3739S.
[10] B.F. Cole, J.A. Baron, R.S. Sandler, R.W. Haile, D.J. Ahnen, R.S. Bresalier, G.
McKeown-Eyssen, R.W. Summers, R.I. Rothstein, C.A. Burke, et al., Folic acid for
the prevention of colorectal adenomas: a randomized clinical trial, JAMA 297
(2007) 2351–2359.
[11] W. He, S.A. Kularatne, K.R. Kalli, F.G. Prendergast, R.J. Amato, G.G. Klee, L.C.
Hartmann, P.S. Low, Quantitation of circulating tumor cells in blood samples
from ovarian and prostate cancer patients using tumor-speciﬁc ﬂuorescent
ligands, Int. J. Cancer 123 (2008) 1968–1973.
[12] S.A. Kularatne, Z. Zhou, J. Yang, C.B. Post, P.S. Low, Design, synthesis, and preclin-
ical evaluation of prostate-speciﬁc membrane antigen targeted (99m)
Tc-radioimaging agents, Mol. Pharm. 6 (2009) 790–800.
[13] L. Pickell, K. Brown, D. Li, X.L. Wang, L. Deng, Q. Wu, J. Selhub, L. Luo, L.
Jerome-Majewska, R. Rozen, High intake of folic acid disrupts embryonic devel-
opment in mice, Birth Defects Res. A Clin. Mol. Teratol. 91 (2011) 8–19.
[14] A. Marean, A. Graf, Y. Zhang, L. Niswander, Folic acid supplementation can ad-
versely affect murine neural tube closure and embryonic survival, Hum. Mol.
Genet. 20 (2011) 3678–3683.
[15] M.S. Jhaveri, C. Wagner, J.B. Trepel, Impact of extracellular folate levels on global
gene expression, Mol. Pharmacol. 60 (2001) 1288–1295.
[16] M. Balaghi, C. Wagner, DNA methylation in folate deﬁciency: use of CpG methyl-
ase, Biochem. Biophys. Res. Commun. 193 (1993) 1184–1190.
[17] K.J. Sohn, J.M. Stempak, S. Reid, S. Shirwadkar, J.B. Mason, Y.I. Kim, The effect of
dietary folate on genomic and p53-speciﬁc DNA methylation in rat colon, Carci-
nogenesis 24 (2003) 81–90.
[18] J.W. Crott, Z. Liu, M.K. Keyes, S.W. Choi, H. Jang, M.P. Moyer, J.B. Mason, Moderate
folate depletion modulates the expression of selected genes involved in cell cycle,
intracellular signaling and folate uptake in human colonic epithelial cell lines,
J. Nutr. Biochem. 19 (2008) 328–335.
[19] P. Protiva, J.B. Mason, Z. Liu, M.E. Hopkins, C. Nelson, J.R. Marshall, R.W.
Lambrecht, S. Pendyala, L. Kopelovich, M. Kim, et al., Altered folate availability
modiﬁes the molecular environment of the human colorectum: implications for
colorectal carcinogenesis, Cancer Prev. Res. (Phila.) 4 (2011) 530–543.
[20] C. Kappen, Disruption of the homeobox gene Hoxb-6 results in increased num-
bers of early erythrocyte progenitors, Am. J. Hematol. 65 (2000) 111–118.
[21] K.U. Wagner, K. McAllister, T. Ward, B. Davis, R. Wiseman, L. Hennighausen, Spa-
tial and temporal expression of the Cre gene under the control of the MMTV-LTR
in different lines of transgenic mice, Transgenic Res. 10 (2001) 545–553.
[22] G. Pavlinkova, J.M. Salbaum, C. Kappen, Maternal diabetes alters transcriptional
programs in the developing embryo, BMC Genomics 10 (2009) 274.
[23] P. Baldi, A.D. Long, A Bayesian framework for the analysis of microarray expres-
sion data: regularized t-test and statistical inferences of gene changes, Bioinfor-
matics 17 (2001) 509–519.
[24] M.A. Kayala, P. Baldi, Cyber-T web server: differential analysis of high-throughput
data, Nucleic Acids Res. 40 (2012) W553–W559.
[25] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources, Nat. Protoc. 4 (2009)
44–57.
1661J.M. Salbaum et al. / Biochimica et Biophysica Acta 1832 (2013) 1653–1661[26] C. Kruger, C. Kappen, Expression of cartilage developmental genes in Hoxc8- and
Hoxd4-transgenic mice, PLoS One 5 (2010) e8978.
[27] J.M. Salbaum, C. Kruger, X. Zhang, N.A. Delahaye, G. Pavlinkova, D.H. Burk, C.
Kappen, Altered gene expression and spongiotrophoblast differentiation in placenta
from a mouse model of diabetes in pregnancy, Diabetologia 54 (2011) 1909–1920.
[28] J.M. Salbaum, Punc, a novel mouse gene of the immunoglobulin superfamily, is
expressed predominantly in the developing nervous system, Mech. Dev. 71
(1998) 201–204.[29] T. Yamaguchi, K. Hirota, K. Nagahama, K. Ohkawa, T. Takahashi, T. Nomura, S.
Sakaguchi, Control of immune responses by antigen-speciﬁc regulatory T cells ex-
pressing the folate receptor, Immunity 27 (2007) 145–159.
[30] J.D. Gray, G. Nakouzi, B. Slowinska-Castaldo, J.E. Dazard, J.S. Rao, J.H. Nadeau, M.E.
Ross, Functional interactions between the LRP6 WNT co-receptor and folate sup-
plementation, Hum. Mol. Genet. 19 (2010) 4560–4572.
[31] O. Stanger, W. Wonisch, Enzymatic and non-enzymatic antioxidative effects of
folic acid and its reduced derivates, Subcell. Biochem. 56 (2012) 131–161.
